Even with Gates’s generous grubstake, GSK’s crooked clinical trial researchers could only muster a feeble claim of 30 percent efficacy for their infanticidal jab.44 Undaunted, Gates rolled out Mosquirix in 2019 as the first malaria vaccine in sub-Saharan Africa. It turned out to be another “genocide-for-girls” project. According to the publication Science, “Mosquirix’s efficacy and durability are mediocre. Four doses offer only 30 percent protection against severe malaria, for no more than 4 years. . . . The biggest concerns, however, are about the vaccine’s safety.” BMJ’s associate editor,
...more
